Napoli C, Leccese M, Palumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, Di Loreto M, De Matteis C, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento F P
Department of Clinical and Experimental Medicine, University of Naples, Italy.
Coron Artery Dis. 1998;9(5):257-64. doi: 10.1097/00019501-199809050-00003.
The enzyme lecithin-cholesterol acyl transferase (LCAT) esterifies free cholesterol on high-density lipoprotein (HDL) and the cholesteryl ester transfer protein (CETP) transfers cholesteryl ester to very-low-density lipoprotein (VLDL) and low-density lipoproteins (LDL). Using statins, contradictory findings have been made regarding CETP activity in normolipidemic individuals and in those with familial dysbetalipoproteinemia. In contrast, LCAT activity appears to be unaffected by simvastatin. Antioxidants have also been proposed for the use of anti-atherosclerotic treatment, because the oxidation of LDL may have a key role in the pathophysiology of atherogenesis.
To investigate, in hypercholesterolemic patients, whether a combination of pravastatin with the antioxidant, vitamin E, has greater effects on the activity of CETP and of LCAT than does pravastatin alone.
This placebo-diet-controlled multicenter trial included 220 hypercholesterolemic patients who were assigned randomly to groups to receive: diet and 20-40 mg pravastatin (n = 52), diet and alpha-tocopherol (n = 60), or diet associated with placebo (n = 52). Plasma LCAT activity was determined using excess exogenous substrate, containing [3H]cholesterol. Plasma CETP activity was measured in the supernatant fraction after precipitation of endogenous apo B-containing lipoproteins with phosphotungstate-Mg2+. The exchange of cholesteryl esters between [14C]cholesteryl ester-labeled LDL and unlabeled HDL was measured during a 16-h incubation, while LCAT was inhibited.
The addition of pravastatin to the diet induced a significant decrease in plasma CETP activity (P < 0.05); this effect was less evident in the group cotreated with vitamin E. For the first time, it was shown that CETP concentrations increased significantly after vitamin E alone (P < 0.05). No significant differences in the plasma activity of LCAT were observed among the groups.
Pravastatin reduced CETP activity, but not that of LCAT. Addition of vitamin E prevented the decrease in CETP activity and had no effect on LCAT activity. The mechanism responsible for these effects is unknown, but could involve the prevention of radical-induced damage to CETP by vitamin E.
卵磷脂胆固醇酰基转移酶(LCAT)可使高密度脂蛋白(HDL)上的游离胆固醇酯化,而胆固醇酯转运蛋白(CETP)则将胆固醇酯转运至极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)。使用他汀类药物时,在血脂正常个体和家族性异常β脂蛋白血症患者中关于CETP活性的研究结果相互矛盾。相比之下,辛伐他汀似乎不影响LCAT活性。抗氧化剂也被提议用于抗动脉粥样硬化治疗,因为LDL的氧化可能在动脉粥样硬化发生的病理生理学中起关键作用。
在高胆固醇血症患者中研究普伐他汀与抗氧化剂维生素E联合使用对CETP和LCAT活性的影响是否大于单独使用普伐他汀。
这项安慰剂饮食对照的多中心试验纳入了220例高胆固醇血症患者,他们被随机分组接受:饮食加20 - 40 mg普伐他汀(n = 52)、饮食加α-生育酚(n = 60)或饮食加安慰剂(n = 52)。使用含[3H]胆固醇的过量外源性底物测定血浆LCAT活性。用磷钨酸盐 - Mg2+沉淀内源性含载脂蛋白B的脂蛋白后,在上清液部分测量血浆CETP活性。在16小时孵育期间,当LCAT被抑制时,测量[14C]胆固醇酯标记的LDL与未标记的HDL之间胆固醇酯的交换。
饮食中添加普伐他汀可使血浆CETP活性显著降低(P < 0.05);在与维生素E联合治疗组中这种作用不太明显。首次发现单独使用维生素E后CETP浓度显著升高(P < 0.05)。各组之间未观察到血浆LCAT活性有显著差异。
普伐他汀降低了CETP活性,但未降低LCAT活性。添加维生素E可防止CETP活性降低,且对LCAT活性无影响。造成这些影响的机制尚不清楚,但可能涉及维生素E预防自由基对CETP的损伤。